Kite Pharma

Gilead's Kite exits China cell therapy joint venture with Fosun Pharma
Fierce Pharma
Thu, 09/19/24 - 09:22 pm
Gilead Sciences
Kite Pharma
China
Fosun Kite Biotechnology
Fosun Pharma
Kyverna swaps CEOs, leaning on Kite veterans to lead ‘next chapter’
BioPharma Dive
Mon, 09/16/24 - 10:14 pm
Kyverna Therapeutics
Gilead Sciences
Kite Pharma
CAR-T
cell therapy
Biotech faces a reckoning: ‘We've lost our luster in cell therapies’
Fierce Biotech
Wed, 05/29/24 - 09:23 pm
cell therapy
Gilead Sciences
Kite Pharma
Kite and Arcellx prepare to launch Phase III multiple myeloma trial
Clinical Trials Arena
Mon, 05/13/24 - 11:22 am
Kite Pharma
Gilead Sciences
Arcellx
clinical trials
anito-cel
Multiple Myeloma
Gilead’s Kite Gets FDA Approval for Faster CAR T Therapy Manufacturing
BioSpace
Wed, 01/31/24 - 11:58 am
Gilead Sciences
Kite Pharma
FDA
drug manufacturing
Yescarta
CAR-T
Gilead cuts 7% of staff at Kite Pharma unit as 'refreshed business strategy' introduced
Fierce Pharma
Wed, 11/29/23 - 11:55 am
Kite Pharma
Gilead Sciences
layoffs
Gilead’s Kite Expands Arcellx Pact with $285M Equity Investment, Upfront Cash
BioSpace
Wed, 11/15/23 - 11:11 am
Gilead Sciences
Kite Pharma
Arcellx
CART-ddBCMA
lymphoma
Kite publishes Phase II data for Yescarta in treating B-cell lymphoma
Clinical Trials Arena
Mon, 09/18/23 - 09:53 am
Gilead Sciences
Kite Pharma
Yescarta
clinical trials
CAR-T
relapsed or refractory large B-cell lymphoma
Kite's Yescarta CAR T-cell Therapy Shows Extended Survival in Relapsed/Refractory Large B-cell Lymphoma
Businesswire
Tue, 06/6/23 - 10:11 am
ASCO 2023
Gilead Sciences
Kite Pharma
Yescarta
relapsed or refractory large B-cell lymphoma
Gilead picks former Roche executive to run cell therapy unit Kite
BioPharma Dive
Wed, 05/17/23 - 11:14 am
Gilead Sciences
Roche
Kite Pharma
cell therapy
Cindy Perettie
women executives
After years of back-and-forth, Gilead's CAR-T Yescarta sways England's cost watchdog NICE
Fierce Pharma
Thu, 01/26/23 - 10:40 am
Gilead Sciences
CAR-T
Yescarta
UK
NICE
Kite Pharma
Novartis
blood cancer
Kite swoops in to buy Carl June-founded Tmunity, gaining key to Penn's CAR-T research apparatus
Fierce Biotech
Tue, 12/20/22 - 11:17 am
Kite Pharma
Gilead Sciences
M&A
CAR-T
Tmunity
Carl June
Gilead lands new cell therapy for Kite in $225M Arcellx deal
Fierce Biotech
Fri, 12/9/22 - 10:37 am
Gilead Sciences
Kite Pharma
Arcellx
clinical trials
Multiple Myeloma
cell therapy
JNJ
Legend Biotech
Gilead dodges Supreme Court review—and a $1.2B fine—in CAR-T patent feud with Bristol Myers
Fierce Pharma
Mon, 11/7/22 - 05:48 pm
Gilead Sciences
Kite Pharma
Bristol Myers Squibb
cell therapy
legal
CAR-T
Yescarta
FDA Review: Alnylam, Cytokinetics, Eli Lilly and More
BioSpace
Sun, 10/9/22 - 06:06 pm
FDA
Alnylam
Cytokinetics
Eli Lilly
Owlet
Boston Cell Standards
Kiromic Biopharma
Entera Bio
Transcenta Holdings
Kira Pharmaceuticals
Kite Pharma
Poxel
Seneca Therapeutics
Gilead hits back at Bristol Myers' Supreme Court petition in CAR-T patent feud
Fierce Pharma
Sun, 08/28/22 - 10:19 pm
Gilead Sciences
CAR-T
patents
Supreme Court
Kite Pharma
Bristol Myers Squibb
Kite’s Maryland CAR T-cell therapy site gets FDA go-ahead
Biopharma Reporter
Wed, 04/20/22 - 10:43 am
Kite Pharma
Gilead Sciences
FDA
CAR-T
drug manufacturing
Yescarta
Gilead beats BMS to FDA okay for early lymphoma CAR-T therapy
Pharmaforum
Mon, 04/4/22 - 10:18 am
Gilead Sciences
Kite Pharma
CAR-T
Bristol Myers Squibb
lymphoma
large B-cell lymphoma
Kite gets US FDA approval for Tecartus to treat acute lymphoblastic leukemia
Pharmaceutical Business Review
Mon, 10/4/21 - 10:39 am
Kite Pharma
Gilead Sciences
Tecartus
FDA
ALL
acute lymphoblastic leukemia
Gilead wins reversal of $1.2B fine in CAR-T patent fight with Bristol Myers
Fierce Pharma
Thu, 08/26/21 - 08:52 pm
Gilead Sciences
Kite Pharma
CAR-T
patents
Bristol Myers Squibb

Pages